Not applicableEnded earlyNCT05571670What this trial is testingBile Acids in Acute Insulin ResistanceWho this might be right forPI3K Gene MutationAKT Gene MutationMTOR Gene Mutation+2 more Columbia University 3
Testing effectiveness (Phase 2)Ended earlyNCT02315625What this trial is testingStudy of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryWho this might be right forNeuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Neoplasms+2 more National Cancer Institute (NCI) 16
Testing effectiveness (Phase 2)Ended earlyNCT02644122What this trial is testingSF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway GenesWho this might be right forMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Ezra Cohen 1
Early research (Phase 1)Ended earlyNCT02476955What this trial is testingOpen-label Phase 1b Study of ARQ 092 in Combination With AnastrozoleWho this might be right forSolid TumorsOvarian CancerEndometrial Cancer ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 41
Not applicableStudy completedNCT05054166What this trial is testingEfficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations StudyWho this might be right forBreast CancerPI3K/AKT/mTOR Pathway MutationEverolimus Zhejiang Cancer Hospital 14
Testing effectiveness (Phase 2)Study completedNCT02201212What this trial is testingEverolimus for Cancer With TSC1 or TSC2 MutationWho this might be right forTSC1TSC2Tuberous Sclerosis Complex+1 more Dana-Farber Cancer Institute 30
Testing effectiveness (Phase 2)Looking for participantsNCT06463028What this trial is testingSapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerWho this might be right forEndometrial Cancer Faeth Therapeutics 40
Early research (Phase 1)Study completedNCT01596140What this trial is testingVemurafenib in Combination With Everolimus or Temsirolimus With Advanced CancerWho this might be right forAdvanced CancerSolid Tumor M.D. Anderson Cancer Center 27
Testing effectiveness (Phase 2)Ended earlyNCT03740100What this trial is testingSingle-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function MutationsWho this might be right forHNSCC M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Study completedNCT04094675What this trial is testingSirolimus for Cowden Syndrome With Colon PolyposisWho this might be right forPTEN Gene MutationPTEN Hamartoma Tumor SyndromePTEN Hamartoma Syndrome+4 more Ohio State University 5
Early research (Phase 1)Study completedNCT01473095What this trial is testingPhase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant LymphomaWho this might be right forSolid TumorMalignant LymphomaTumor ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 120
Testing effectiveness (Phase 2)Study completedNCT03190174What this trial is testingNivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain CancersWho this might be right forEwing SarcomaPEComaEpithelioid Sarcoma+11 more Sarcoma Oncology Research Center, LLC 34
Testing effectiveness (Phase 2)Active Not RecruitingNCT05103358What this trial is testingPhase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)Who this might be right forTumorTumor, SolidMetastasis+18 more Aadi Bioscience, Inc. 120
Testing effectiveness (Phase 2)Study completedNCT06132932What this trial is testingWX390 in Patients With Advanced Solid Tumors With PIK3CA MutationsWho this might be right forPIK3CA Mutation-Related Tumors Shanghai Jiatan Pharmatech Co., Ltd 38
Not applicableNot Yet RecruitingNCT07387861What this trial is testingPI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic StudyWho this might be right forBreast Cancer - ER+, HER2-, PIK3CA Gene Mutation Assiut University 70
Large-scale testing (Phase 3)Looking for participantsNCT05954442What this trial is testingEverolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypeWho this might be right forTriple Negative Breast CancerMetastatic Breast CancerMutation Fudan University 203
Not applicableUnknownNCT04112537What this trial is testingDermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation RelationshipWho this might be right forTuberous Sclerosis Complex University Hospital, Montpellier 90
Early research (Phase 1)Active Not RecruitingNCT02208375What this trial is testingMTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianWho this might be right forBRCA1 Mutation CarrierBRCA2 Mutation CarrierEndometrial Adenocarcinoma+13 more M.D. Anderson Cancer Center 159
Early research (Phase 1)Ended earlyNCT05840510What this trial is testingAdagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)Who this might be right forSolid Tumor, AdultNSCLCAdvanced Cancer+2 more Mirati Therapeutics Inc. 6
Not applicableLooking for participantsNCT04395495What this trial is testingRASopathy BiorepositoryWho this might be right forRAS MutationNeurofibromatosis 1Noonan Syndrome+11 more Children's Hospital Medical Center, Cincinnati 1,000